Table 1.

Characteristics of glioma patients and controls

Clinical features	Glioma cases										Controls										P b
	All			A*02:01 (+)			A*02:01 (−)			P a	All			A*02:01 (+)			A*02:01 (−)			P a
	No.		%	No.		%	No.		%		No.		%	No.		%	No.		%
Total	150		100	24		16	126		84	–	150		100	49		32.7	101		67.3	–	0.001
Age																					0.509
Mean		47.4			43.8			47.0		0.208		46.5			49.6			46.4		0.139
SD		12.3			9.7			11.6				11.4			13.0			12.0
Sex																					–
Male	85		56.7	15		62.5	70		55.6	0.529	85		56.7	29		59.2	56		55.4	0.665
Female	65		43.3	9		37.5	56		44.4		65		43.3	20		40.8	45		44.6
Gliomas
Low-grade	33		22	5		20.8	28		22.2	0.880	–		–	–		–	–		–	–
High-grade	117		78	19		79.2	98		77.8		–		–	–		–	–		–
IDH1/2
Mutated	51		34	9		37.5	42		33.3	0.693	–		–	–		–	–		–	–
Wild-type	99		66	15		62.5	84		66.7		–		–	–		–	–		–
MGMT
Methylated	59		39.3	11		45.8	48		38.1	0.477	–		–	–		–	–		–	–
Unmethylated	91		60.7	13		54.2	78		61.9		–		–	–		–	–		–
IE1-72
Positive	117		78	6		25	111		88.1	0.001	–		–	–		–	–		–	–
Negative	33		22	18		75	15		11.9		–		–	–		–	–		–
pp65
Positive	99		66	6		25	93		73.8	0.001	–		–	–		–	–		–	–
Negative	51		44	18		75	33		26.2		–		–	–		–	–		–
HCMV DNA
Positive	48		32	2		8.3	46		36.5	0.007	–		–	–		–	–		–	–
Negative	102		68	22		91.7	80		63.5		–		–	–		–	–		–
HCMV IgG																					0.602
Positive	112		74.7	15		62.5	97		77.0	0.135	108		72.0	32		65.3	76		75.2	0.203
Negative	38		25.3	9		37.5	29		23.0		42		28.0	17		34.7	25		24.8
HCMV IgM																					0.442
Positive	28		18.7	1		4.2	27		21.4	0.047	23		15.3	3		6.1	20		19.8	0.029
Negative	122		81.3	23		95.8	99		78.6		127		84.7	46		93.9	81		80.2

Statistically significant P values <0.05 are italicized

^aA*02:01 (+) vs A*02:01 (−)

^bCases vs controls